Ravulizumab Showed Preclinical Promise for ALS. What Happened?

(MedPage Today) -- Ravulizumab (Ultomiris), a terminal complement C5 inhibitor, did not improve functional status and survival in patients with amyotrophic lateral sclerosis (ALS), the phase III CHAMPION-ALS trial showed.
No significant difference...

Source: MedPage Today Neurology - September 11, 2023 Category: Neurology Source Type: news